Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01257
|
|||||
| Drug Name |
Gadobenate dimeglumine
|
|||||
| Synonyms |
Multihance Multipack; Multihance; Gd-Bopta/dimeg; Gadobenate dimeglumine; Gadobenic acid dimeglumine salt; Gadobenate Dimeglumine [USAN]; B 1903617; Gadobenic acid; 127000-20-8; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | CNS imaging [ICD11: XD47Y1] | Approved | [1] | |||
| Therapeutic Class |
Contrast Media
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C36H62GdN5O21
|
|||||
| Canonical SMILES |
[H+].[H+].CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]
|
|||||
| InChI |
InChI=1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
|
|||||
| InChIKey |
OCDAWJYGVOLXGZ-VPVMAENOSA-K
|
|||||
| CAS Number |
CAS 127000-20-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 1058.1 | Topological Polar Surface Area | 446 | ||
| Heavy Atom Count | 63 | Rotatable Bond Count | 16 | |||
| Hydrogen Bond Donor Count | 14 | Hydrogen Bond Acceptor Count | 26 | |||
| PubChem CID | ||||||
| PubChem SID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
| References | ||||||
| 1 | Gadobenate dimeglumine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.